The world needs Inavir but the duel ownership has not allowed a commercial deal for row to ve struck. Hence BARDA funds were needed to accelerate development. Of course Japan trials did process efficacy, they just need to prove it in the USA. Phase 2 and 3 trials needed which will take some years. The DS/BTA partnership can go it alone for the stockpiling market. Hope they can split the spoils equitably given it is BTA who won the BARDA grant and hence can pull the plug?
BTA Price at posting:
97.5¢ Sentiment: Buy Disclosure: Held
